GENENTECH, INC.
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 181
- Registration Number
- NCT03332797
- Locations
- πͺπΈ
Hospital Quiron Barcelona, Barcelona, Spain
πͺπΈHospital Universitari Vall d'Hebron, Barcelona, Spain
πͺπΈHospital General Universitario Gregorio Maranon, Madrid, Spain
A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
- First Posted Date
- 2017-10-02
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT03298516
- Locations
- πΊπΈ
Columbia University Medical Center; Research Pharmacy, Irving Pavillion, Ip 7-749, New York, New York, United States
π¨π¦Jewish General Hospital / McGill University, Montreal, Quebec, Canada
π¨π¦University of Alberta Hospital, Edmonton, Alberta, Canada
Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
- First Posted Date
- 2017-09-28
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT03295877
- Locations
- πΊπΈ
Retina Specialty Institute, Pensacola, Florida, United States
πΊπΈCalifornia Retina Consultants - Santa Maria, Santa Maria, California, United States
πΊπΈRetina Consultants of Southern Colorado PC; Clinical Research Department, Colorado Springs, Colorado, United States
A Study to Investigate the Effect of Formulation, Food, and Rabeprazole on the Pharmacokinetics (PK) of GDC-0853 in Healthy Participants
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT03290703
- Locations
- π¬π§
Quotient Clinical Ltd, Clinical Research Unit, Nottingham, United Kingdom
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
- Conditions
- MelanomaTriple Negative Breast CancerRenal CancerBladder CancerColorectal CancerNon-Small Cell Lung CancerOther Solid CancersHead and Neck Cancer
- Interventions
- First Posted Date
- 2017-09-21
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 272
- Registration Number
- NCT03289962
- Locations
- πΊπΈ
Dana Farber Can Ins, Boston, Massachusetts, United States
π¨π¦The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
π¨π¦Princess Margaret Cancer Center, Toronto, Ontario, Canada
A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 457
- Registration Number
- NCT03289143
- Locations
- π΅π±
M.A. - LEK A.M.Maciejowscy SC., Katowice, Poland
π΅π±Novo-Med Zielinski i wspolnicy Sp. j., Katowice, Poland
π΅π±AMED Medical Center, Warszawa, Poland
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2017-09-07
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 420
- Registration Number
- NCT03275103
- Locations
- πͺπΈ
Clinica Universidad de Navarra, Pamplona/iruΓ±a, Navarra, Spain
πͺπΈHospital Clinico Universitario de Salamanca, Salamanca, Spain
π¨π¦Jewish General Hospital, Montreal, Quebec, Canada
Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03237741
- Locations
- π¬π§
Quotient Clinical Ltd, Clinical Research Unit, Nottingham, United Kingdom
A Drug-Drug Interaction Study Between GDC-0853 and Midazolam, Itraconazole, Rosuvastatin, and Simvastatin
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT03174041
- Locations
- πΊπΈ
Covance Research Unit - Daytona, Daytona Beach, Florida, United States
πΊπΈCovance Clinical Research Unit Inc.; Covance Gfi Research, Evansville, Indiana, United States
πΊπΈCovance Clinical Research Unit, Inc, Madison, Wisconsin, United States
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics
- First Posted Date
- 2017-05-22
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT03162250
- Locations
- π°π·
Asan Medical Center - Oncology, Seoul, Korea, Republic of
π°π·Korea University Guro Hospital, Seoul, Korea, Republic of
πΊπΈHenry Ford Health System, Detroit, Michigan, United States